This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Burtness B , Powell M , Catalano P , Berlin J , Liles DK , Chapman AE , Mitchell E , Benson AB
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
Am J Clin Oncol. 2016 Aug;39(4) :340-5
PMID: 24685886 PMCID: PMC4177955
AbstractOBJECTIVES: The primary objective was to determine the response rate in patients with metastatic pancreatic cancer treated in first line with irinotecan/docetaxel combination (Arm A) or with irinotecan/docetaxel/cetuximab combination (Arm B). Secondary endpoints were progression-free survival (PFS), overall survival (OS), toxicity, and the rate of thromboembolic events with prophylactic enoxaparin sodium. PATIENTS AND METHODS: Patients were eligible who had measurable, metastatic adenocarcinoma of the pancreas, and normal bilirubin. All patients received anticoagulation. Docetaxel (35 mg/m) and irinotecan (50 mg/m) were administered once a week for 4 weeks followed by 2 weeks rest (Arm A) alone or with the addition of cetuximab (Arm B). The primary endpoint was response rate. RESULTS: A total of 87 eligible patients were enrolled and treated. Grade 3/4 toxicity was observed in 74% of patients in Arm A and 76% in Arm B. The principal grade 3/4 toxicity was diarrhea. Response rates were 4.5% in Arm A and 7% in Arm B. Median PFS and OS were 3.9 and 6.5 months in Arm A and 4.5 and 5.4 months in Arm B. CONCLUSIONS: Docetaxel/irinotecan combination is associated with considerable toxicity. Objective responses were infrequent and addition of cetuximab in an unselected population was not beneficial, but PFS and OS were comparable with those achieved with other regimens. Docetaxel/irinotecan therapy is active in metastatic pancreatic cancer.
Notes1537-453x Burtness, Barbara Powell, Mark Catalano, Paul Berlin, Jordan Liles, Darla K Chapman, Andrew E Mitchell, Edith Benson, Al B UL1 TR001863/TR/NCATS NIH HHS/United States U10 CA021115/CA/NCI NIH HHS/United States P30 CA060553/CA/NCI NIH HHS/United States U10 CA180820/CA/NCI NIH HHS/United States U10 CA023318/CA/NCI NIH HHS/United States U10 CA180794/CA/NCI NIH HHS/United States Clinical Trial, Phase II Journal Article Randomized Controlled Trial United States Am J Clin Oncol. 2016 Aug;39(4):340-5. doi: 10.1097/COC.0000000000000068.